Enodia Therapeutics, a biotech spin-off from the Institut Pasteur incubated within Argobio Studio, announced on January 8, 2026 a seed round of €20.7 million (approximately $25M). The round was co-led by Elaia, Pfizer Ventures and Bpifrance through its InnoBio strategy, with participation from Wallonie Entreprendre, MACSF, the Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital. It is one of the largest French biotech seed rounds of the season.
A novel approach to targeted protein degradation
According to the official press release carried by BusinessWire, Enodia leverages a small-molecule platform that selectively modulates the SEC61 translocon. This protein complex acts as the gateway through which secreted and transmembrane proteins pass during synthesis. By blocking the passage of a specific target protein at the point of translation, Enodia triggers its degradation at the source — a mechanism very different from PROTAC or molecular glue approaches, which act on proteins that are already mature.
The discovery engine combines two core building blocks:
- Large-scale proteomics to map signal peptide/SEC61 interactions.
- Machine learning to identify signal peptides that can be selectively modulated.
The technology stems from research conducted at the Institut Pasteur, where the founders validated the concept across several inflammatory targets.
A pivotal indication: immuno-inflammation
The initial pipeline targets inflammatory and autoimmune diseases, an area where targeted degradation remains underexplored compared to oncology. Established indications (rheumatoid arthritis, psoriasis, IBD, lupus) still rely heavily on expensive injectable biologics and surface targets. A small molecule capable of degrading an intracellular inflammatory mediator at the very moment it is produced would open up oral therapeutic options — more accessible and more affordable.
Enodia also sees opportunities in oncology and in viral infections, since the SEC61 mechanism is shared by many pathogenic proteins.
Market: a sector valued between $0.5 and $1 billion in 2025, accelerating sharply
According to Fortune Business Insights, the global targeted protein degradation market will reach roughly $1 billion in 2025 and is expected to approach $7 billion by 2035. More aggressive projections, such as those from SkyQuest, put the market at nearly $6 billion as early as 2033 (a CAGR of around 28%).
Three shifts are shaping this momentum:
- Clinical validation of PROTACs, with several candidates in Phase II/III at Arvinas, Kymera, Foghorn, or C4 Therapeutics.
- Accelerating research on molecular glues, whose ease of administration appeals to big pharma.
- A wave of acquisitions and deals, estimated at a cumulative $7 billion between 2025 and 2033, according to analysts.
Pfizer Ventures' investment in Enodia is no accident: Pfizer is active in the segment through several partnerships with Arvinas and has built an internal targeted protein degradation unit. This stake could foreshadow a future co-development option.
Competition: a landscape in two waves
The first TPD wave is dominated by conventional E3 ligase approaches:
- Arvinas (United States): PROTAC pioneer, deals with Pfizer and Roche.
- Kymera Therapeutics: advanced portfolio in oncology and inflammation.
- C4 Therapeutics, Foghorn, Plexium: BiDAC models and diverse platforms.
The second wave, younger, is exploring other mechanisms: targeted autophagy (AUTOTAC), translation inhibition, and — like Enodia — secretion modulation. The specific focus on SEC61 reduces the number of direct competitors and potentially makes it possible to attack targets considered "undruggable" by E3 ligase approaches.
Additional analysis from European Biotechnology Magazine highlights that this round ranks among the largest European biotech seed rounds of the season.
Investor profile and signals for the ecosystem
The investor consortium is itself worth analyzing:
- Elaia and Bpifrance/InnoBio: strong French anchoring, with the capacity to participate in multiple rounds.
- Pfizer Ventures: a high-quality corporate signal, with access to Pfizer's oncology/inflammation pipeline.
- Wallonie Entreprendre, InvestSud, Sambrinvest: a Belgian foothold that paves the way for a potential local presence, as Argobio has done on other deals.
- Mission BioCapital: a US LP that opens the door to a US Series A down the line.
For deeptech startups structuring their scientific AI strategy, the deal illustrates the value of a strong academic sponsor (Pasteur), an experienced biotech studio (Argobio), and a multidimensional investor consortium.
Execution risks
Enodia is still in the preclinical discovery phase. The main risks:
- Selectivity: modulating SEC61 without affecting the other proteins that use the same translocon is a major pharmacological challenge.
- Preclinical candidate selection expected within 12 months — an inflection point that will determine the Series A round.
- Talent competition, particularly in medicinal chemistry and machine learning applied to proteins, in a tight market.
Growth implications for early-stage biotechs
Enodia is a textbook case for deeptech founders structuring their funding trajectory with a growth marketing team on the ecosystem side: upstream scientific alignment (Pasteur), studio incubation (Argobio), a large multi-investor seed round, and a strategic pharma option. This sequence — now the dominant pattern in premium French biotech — shortens time to market while securing the capital needed all the way through IND-enabling studies.
FAQ
How much has Enodia Therapeutics raised?
Enodia closed a €20.7 million seed round (approximately $25 million) announced on January 8, 2026, co-led by Elaia, Pfizer Ventures and Bpifrance/InnoBio.
What is Enodia's technology?
The company develops small molecules that modulate the SEC61 translocon, the portal through which proteins pass during synthesis. This allows it to selectively degrade pathogenic proteins as they are produced, rather than after maturation, as PROTACs or molecular glues do.
Which indications is Enodia targeting?
The initial pipeline targets inflammatory and autoimmune diseases (rheumatoid arthritis, psoriasis, IBD, lupus). The SEC61 mechanism also opens up opportunities in oncology and viral infections.
What will the funds raised be used for?
The €20.7M should enable the selection of a preclinical candidate within the next 12 months — an inflection point paving the way for IND-enabling studies and future clinical phases.
How big is the targeted protein degradation market?
The market is expected to reach around $1 billion in 2025, according to Fortune Business Insights, with projections of roughly $6 to $7 billion by 2033-2035, a CAGR of between 25% and 28% according to analysts.